Literature DB >> 34537845

The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.

Christine L Chan1, Laura Pyle2, Tim Vigers1,2, Philip S Zeitler1, Kristen J Nadeau1.   

Abstract

CONTEXT: Early glucose abnormalities in people with cystic fibrosis (PwCF) are commonly detected by continuous glucose monitoring (CGM). Relationships between these CGM abnormalities and oral glucose tolerance testing (OGTT) in PwCF have not been fully characterized.
OBJECTIVE: This work aimed to determine the relationship between CGM and common OGTT-derived estimates of β-cell function, including C-peptide index and oral disposition index (oDI) and to explore whether CGM can be used to screen for OGTT-defined prediabetes and cystic fibrosis-related diabetes (CFRD).
METHODS: PwCF not on insulin and healthy controls aged 6 to 25 years were enrolled in a prospective study collecting OGTT and CGM. A subset underwent frequently sampled OGTTs (fsOGTT) with 7-point glucose, insulin, and C-peptide measurements. Pearson correlation coefficient was used to test the association between select CGM and fsOGTT measures. Receiver operating curve (ROC) analysis was applied to CGM variables to determine the cutoff optimizing sensitivity and specificity for detecting prediabetes and CFRD.
RESULTS: A total of 120 participants (controls = 35, CF = 85), including 69 with fsOGTTs, were included. CGM coefficient of variation correlated inversely with C-peptide index (Cpeptide30-Cpeptide0/Glucose30-Glucose0) (r = -0.45, P < .001) and oDIcpeptide (C-peptide index)(1/cpep0) (r = -0.48, P < .0001). In PwCF, CGM variables had ROC - areas under the curve ranging from 0.43 to 0.57 for prediabetes and 0.47 to 0.6 for CFRD.
CONCLUSION: Greater glycemic variability on CGM correlated with reduced β-cell function. However, CGM performed poorly at discriminating individuals with and without OGTT-defined CFRD and prediabetes. Prospective studies are now needed to determine how well the different tests predict clinically relevant nonglycemic outcomes in PwCF.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  continuous glucose monitoring; cystic fibrosis–related diabetes; oral disposition index; oral glucose tolerance testing; screening

Mesh:

Substances:

Year:  2022        PMID: 34537845      PMCID: PMC8764335          DOI: 10.1210/clinem/dgab692

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   6.134


  54 in total

1.  Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.

Authors:  M Stumvoll; A Mitrakou; W Pimenta; T Jenssen; H Yki-Järvinen; T Van Haeften; W Renn; J Gerich
Journal:  Diabetes Care       Date:  2000-03       Impact factor: 19.112

Review 2.  2. Classification and Diagnosis of Diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2017-01       Impact factor: 19.112

3.  Screening for cystic fibrosis-related diabetes and prediabetes: Evaluating 1,5-anhydroglucitol, fructosamine, glycated albumin, and hemoglobin A1c.

Authors:  Kalie L Tommerdahl; John T Brinton; Tim Vigers; Kristen J Nadeau; Philip S Zeitler; Christine L Chan
Journal:  Pediatr Diabetes       Date:  2019-10-02       Impact factor: 4.866

4.  Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients.

Authors:  A Leclercq; B Gauthier; V Rosner; L Weiss; F Moreau; A A Constantinescu; R Kessler; L Kessler
Journal:  J Cyst Fibros       Date:  2013-12-17       Impact factor: 5.482

5.  HbA1c as a screening tool for cystic fibrosis related diabetes.

Authors:  Juliana C Burgess; Nicola Bridges; Winston Banya; Khin M Gyi; Margaret E Hodson; Diana Bilton; Nicholas J Simmonds
Journal:  J Cyst Fibros       Date:  2015-04-11       Impact factor: 5.482

6.  Cystic fibrosis-related diabetes is caused by islet loss and inflammation.

Authors:  Nathaniel J Hart; Radhika Aramandla; Gregory Poffenberger; Cody Fayolle; Ariel H Thames; Austin Bautista; Aliya F Spigelman; Jenny Aurielle B Babon; Megan E DeNicola; Prasanna K Dadi; William S Bush; Appakalai N Balamurugan; Marcela Brissova; Chunhua Dai; Nripesh Prasad; Rita Bottino; David A Jacobson; Mitchell L Drumm; Sally C Kent; Patrick E MacDonald; Alvin C Powers
Journal:  JCI Insight       Date:  2018-04-19

7.  Glycaemic regulation and insulin secretion are abnormal in cystic fibrosis pigs despite sparing of islet cell mass.

Authors:  Aliye Uc; Alicia K Olivier; Michelle A Griffin; David K Meyerholz; Jianrong Yao; Maisam Abu-El-Haija; Katherine M Buchanan; Oriana G Vanegas Calderón; Marwa Abu-El-Haija; Alejandro A Pezzulo; Leah R Reznikov; Mark J Hoegger; Michael V Rector; Lynda S Ostedgaard; Peter J Taft; Nick D Gansemer; Paula S Ludwig; Emma E Hornick; David A Stoltz; Katie L Ode; Michael J Welsh; John F Engelhardt; Andrew W Norris
Journal:  Clin Sci (Lond)       Date:  2015-01       Impact factor: 6.124

8.  Elevation of 1-hour plasma glucose during oral glucose tolerance testing is associated with worse pulmonary function in cystic fibrosis.

Authors:  Jill Brodsky; Shayne Dougherty; Ramkrishna Makani; Ronald C Rubenstein; Andrea Kelly
Journal:  Diabetes Care       Date:  2011-01-12       Impact factor: 19.112

9.  Delayed glucose peak and elevated 1-hour glucose on the oral glucose tolerance test identify youth with cystic fibrosis with lower oral disposition index.

Authors:  Kalie L Tommerdahl; John T Brinton; Tim Vigers; Melanie Cree-Green; Philip S Zeitler; Kristen J Nadeau; Christine L Chan
Journal:  J Cyst Fibros       Date:  2020-09-11       Impact factor: 5.482

10.  Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.

Authors:  Kristina M Utzschneider; Ronald L Prigeon; Mirjam V Faulenbach; Jenny Tong; Darcy B Carr; Edward J Boyko; Donna L Leonetti; Marguerite J McNeely; Wilfred Y Fujimoto; Steven E Kahn
Journal:  Diabetes Care       Date:  2008-10-28       Impact factor: 19.112

View more
  3 in total

1.  The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.

Authors:  Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

2.  Inferring Insulin Secretion Rate from Sparse Patient Glucose and Insulin Measures.

Authors:  Rammah M Abohtyra; Christine L Chan; David J Albers; Bruce J Gluckman
Journal:  Front Physiol       Date:  2022-08-03       Impact factor: 4.755

Review 3.  Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review.

Authors:  Shanal Kumar; Michael Pallin; Georgia Soldatos; Helena Teede
Journal:  J Clin Transl Endocrinol       Date:  2022-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.